how do the two approaches to treating high-risk smoldering multiple myeloma (hrsmm) patients differ?
Published 6 years ago • 919 plays • Length 4:40Download video MP4
Download video MP3
Similar videos
-
4:04
how is high-risk smoldering multiple myeloma diagnosed?
-
58:44
treatments available for high risk smoldering myeloma patients
-
4:47
what is high-risk smoldering myeloma? criteria, risks, and ongoing research
-
9:55
curative strategy for high-risk smoldering myeloma: post-hoc analysis of sustained undetectable mrd
-
3:12
qip-mass spectrometry in high risk smoldering multiple myeloma pts included in the gem-cesar trial
-
1:26
identifying high-risk smoldering myeloma & minimizing treatment-related toxicity
-
2:04
ash 2018: earlier smoldering myeloma treatment & the promise study
-
5:27
when patients test as having borderline high-risk smoldering myeloma, should they receive treatment?
-
2:34
how should smoldering multiple myeloma be monitored?
-
4:12
when should smoldering multiple myeloma patients start treatment?
-
2:52
genomically aggressive or indolent smoldering myeloma and progression to multiple myeloma
-
30:34
smoldering multiple myeloma: early detection and intervention approaches by dr. mark bustoros
-
1:46
study offers new treatment options for high risk smoldering multiple myeloma
-
15:50
understanding car t therapy: a groundbreaking approach to myeloma treatment
-
3:48
the importance of treating patients with smoldering myeloma at high risk of progression to myeloma
-
3:37
irene ghobrial: preventing progression from smoldering to symptomatic myeloma
-
5:26
maintenance therapy in multiple myeloma: phetema study in high risk smoldering multiple myeloma
-
3:11
what is hrsmm? what are the guidelines?
-
5:16
updated risk stratification model for smoldering multiple myeloma